Results 41 to 50 of about 13,220 (219)

Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature

Antibiotics, 2023
Bone and joint infections (BJIs) caused by multidrug-resistant gram-negative bacteria are becoming a concern due to limited therapeutic options. Although not approved for these indications, an ever-growing amount of evidence supports the efficacy and ...
Alessandro Mancuso, Luca Pipitò, Raffaella Rubino, Salvatore Antonino Distefano, Donatella Mangione, Antonio Cascio   +5 more
doaj   +1 more source

Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC- producing Enterobacteriaceae [PDF]

, 2018
Introduction: Difficult Gram-negative infections are increasingly treated with new β-lactamase inhibitor combinations, e.g. ceftazidime/avibactam.
Doumith, Michel, Jamrozy, Dorota, Livermore, David M., Mushtaq, Shazad, Nichols, Wright W., Woodford, Neil   +5 more
core   +1 more source

identifying allosteric networks to fight antibiotics resistance [PDF]

, 2018
The rise of multi-drug resistance in bacterial pathogens is one of the grand challenges facing medical science. A major concern is the speed of development of β-lactamase-mediated resistance in Gram-negative species, thus putting at risk the efficacy of ...
Afsharikho, Hamidreza, Barnes, Melissa D., Bonomo, Robert A., Galdadas, Ioannis, Gervasio, Francesco L., Haider, Shozeb, Healy, Jess, Lovera, Silvia, Pérez-Hernández, Guillermo, Woodford, Neil   +9 more
core   +1 more source

Outbreak of Klebsiella pneumoniae ST11 Resistant To Ceftazidime-Avibactam Producing KPC-31 and the Novel Variant KPC-115 during COVID-19 Pandemic in Argentina

Microbiology Spectrum, 2022
We describe an outbreak of Klebsiella pneumoniae sequence type 11 (ST11) producing KPC variants resistant to ceftazidime-avibactam. Six patients hospitalized in the intensive care unit (mostly due to critical COVID pneumonia) presented infection or ...
Federico Nicola, Daniela Cejas, Francisco González-Espinosa, Silvia Relloso, Fabián Herrera, Pablo Bonvehí, Jorgelina Smayevsky, Roque Figueroa-Espinosa, Gabriel Gutkind, Marcela Radice   +9 more
doaj   +1 more source

New antimicrobials [PDF]

, 2017
Since 2010 the new antimicrobials introduced have activity against resistant Gram negative bacteria, long half-lives against Gram positive bacteria, better activity against Clostridium difficile, and safer antifungal properties. Limiting factors to using
Roland, Will
core   +1 more source

Treatment of infections caused by multidrug-resistant Gram-negative bacteria:Report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party [PDF]

, 2018
The Working Party makes more than 100 tabulated recommendations in antimicrobial prescribing for the treatment of infections caused by multidrug-resistant (MDR) Gram-negative bacteria (GNB) and suggest further research, and algorithms for hospital and ...
Enoch, David A, Hawkey, Peter M, Livermore, David M, McNulty, Cliodna A M, Otter, Jonathan A, Warren, Roderic E, Wilson, A Peter R   +6 more
core   +1 more source

Successful Treatment of Acute Prostatitis Caused by Multidrug-Resistant Escherichia coli With Tigecycline Monotherapy [PDF]

, 2020
We present a successful treatment, with tigecycline monotherapy, of acute prostatitis caused by multidrug-resistant Escherichia coli harboring an NDM-1 carbapemenase along with a CMY-2 cephalosporinase and a TEM ...
Babouee Flury, Baharak, Buetti, Niccolo, Casanova, Carlo, Furrer, Hansjakob, Jent, Philipp, Livermore, David M, Lo Priore, Elia, Pelzer, Niklas   +7 more
core   +2 more sources

Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA) [PDF]

, 2016
Intra-abdominal infections (IAI) are an important cause of morbidity and are frequently associated with poor prognosis, particularly in high-risk patients.
A, A, A, A, A, A, A, A, A, A, A, A, A, AA, AC, AH, AJ, AK, AK, AM, AW, B, B, B, B, BJ, C, C, C, C, CA, CA, CE, D, D, D, DG, DP, E, EA, EE, F, F, F, F, FA, FM, FM, G, G, G, G, G, G, G, GA, GP, H, H, H, H, HAS, HE, I, I, I, I, IJ, J, J, JA, JE, JF, JG, JJ, JJ, JL, JR, JR, JR, JV, K, K, K, K, KA, KC, KYY, L, LJ, M, M, M, M, M, M, M, M, M, M, M, M, M, MA, MA, MA, MA, MC, MG, MM, MN, MP, N, N, NT, O, OR, P, P, P, P, PF, PK, R, R, R, R, R, R, R, RB, RG, RM, RR, RR, RS, RV, S, S, S, S, S, S, S, S, S, Sartelli, SJ, SK, SK, SM, SR, SR, SY, T, T, TL, TM, V, V, VG, VN, W, W, W, WL, WR, Y, YF, YH, YR, YS, Z, ZJ   +173 more
core   +16 more sources

A prospective one-year microbiologic survey of combined pneumonia and respiratory failure [PDF]

, 2017
Background: Pneumonia and respiratory failure are common problems in the intensive care unit (ICU) setting, often occurring together. The relative prevalence of pneumonia types (community acquired, hospital acquired, ventilator associated) and causative ...
Fisher, Kristen, Juang, Paul, Kollef, Marin H, Micek, Scott T, Trupka, Tracy   +4 more
core   +2 more sources

WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases [PDF]

, 2017
Background: Several diazabicyclooctanes (DBOs) are under development as inhibitors of Class A and C -lactamases. Inhibition of OXA (Class D) carbapenemases is variable, with those of Acinetobacter spp. remaining notably resistant. We describe a novel DBO,
Anna Vickers, Clinical and Laboratory Standards Institute, David M. Livermore, Neil Woodford, Shazad Mushtaq   +4 more
core   +1 more source